Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

Key Takeaways

• FcRn-targeting agents for gMG vary in their mechanisms, primarily by inhibiting FcRn to lower pathogenic IgG levels or modulating immune responses.
• Both approved and investigational FcRn-targeting drugs possess distinct pharmacological profiles, impacting their therapeutic applications.
• The development of these therapies marks a significant advancement in gMG management, enhancing treatment options and patient outcomes.